Description
Indications of Nexum MUPS 20
- Gastro-esophageal Reflux Disease (GERD) is treated with esomeprazole MUPS tablets (GERD).
- NSAID-related stomach ulcer risk is reduced.
- Eradication of Helicobacter pylori (Triple therapy).
- Idiopathic hypersecretion and Zollinger-Ellison syndrome
Pharmacology of Nexum MUPS 20
Nexum MUPS 20 is a proton pump inhibitor that inhibits the H+/K+ ATPase in the gastric parietal cell, suppressing gastric acid production. The first single optical isomer of a proton pump inhibitor, esomeprazole (S-isomer of omeprazole), provides superior acid control than racemic proton pump inhibitors.
Dosage & Administration of Nexum MUPS 20
Erosive esophagitis-
- Adult (≥18 years): 40 mg once daily for 4 weeks.
- Children & adolescents (12-18 years): 40 mg once daily for 4 weeks.
Maintenance of healing of erosive esophagitis-
- Adult (≥18 years): 20 mg once daily.
- Children & adolescents (12-18 years): 20 mg once daily.
Risk reduction in NSAID associated gastric ulcer-
- Adult (≥18 years): 20 mg once daily for 4-8 weeks.
- pylori eradication (Esomeprazole MUPS tablet with 1000 mg Amoxicillin and 500 mg Clarithromycin)-
- Adult (≥18 years): 20 mg twice daily for 7 days.
- Children & adolescents (12-18 years): 20 mg twice daily for 7 days.
Zollinger-Ellison syndrome and idiopathic hypersecretion-
- Adult (≥18 years): 40-80 mg twice daily.
Children 1-11 years:
- Erosive esophagitis: Weight <20 kg: 10 mg once daily for 8 weeks. Weight ≥20 kg: 10 mg or 20 mg once daily for 8 weeks
- Maintenance of healing of erosive esophagitis: 10 mg once daily
Children below the age of 1 year: Esomeprazole MUPS tablet is not approved for use in children younger than 1 year.
Interaction of Nexum MUPS 20
CYP2C19 and CYP3A4 substantially metabolize esomeprazole in the liver. Esomeprazole does not appear to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1, or 3A4 in vitro or in vivo investigations. There should be no clinically significant interactions with medicines processed by these CYP enzymes. Esomeprazole has no clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin, or amoxicillin, according to drug interaction studies.
The primary Esomeprazole metabolizing enzyme, CYP2C19, may be harmed by Esomeprazole. The combination of Esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45 percent reduction in diazepam clearance. Increased diazepam plasma levels have been reported up to 12 hours following treatment. Gastric acid secretion is inhibited by esomeprazole. As a result, Esomeprazole may interfere with the absorption of medicines whose bioavailability is influenced by stomach pH. (e.g., ketoconazole, iron salts and digoxin).
Contraindications
In patients who have a history of hypersensitivity to any of the formulations, esomeprazole is not recommended.
Side Effect of Nexum MUPS 20
Headache, diarrhoea, nausea, flatulence, stomach discomfort, constipation, and dry mouth are the most common side effects reported with Esomeprazole. When compared to short-term treatment, there is no change in the kinds of linked adverse events reported with maintenance treatment up to 12 months.
Pregnancy & Lactation
Caution is advised by the manufacturer. Esomeprazole or its metabolites are not known to occur in human breast milk.
Precautions & Warnings
If the patient has significant liver failure and renal impairment, esomeprazole should be taken with caution. Proton pump inhibitors, such as Esomeprazole, may modestly increase the risk of hip, wrist, and spine fractures, especially when used for more than a year.
Therapeutic Class
Proton Pump Inhibitor
Storage Conditions
Store in a dry location at a temperature of not more than 25°C. Light and dampness should be avoided. Keep out of children’s reach.
Pharmaceutical Name of Nexum MUPS 20
Square Pharmaceuticals Ltd
Generic of Nexum MUPS 20
Esomeprazole Magnesium Trihydrate
